Literature DB >> 17897564

Management of ventricular tachycardia in the absence of structural heart disease.

Daniel P Morin1, Bruce B Lerman.   

Abstract

Ventricular tachycardia most often arises from the ventricular outflow tracts in patients with apparently structurally normal hearts, and is often termed idiopathic ventricular tachycardia. These tachycardias are characterized by a left bundle branch block, inferior axis QRS morphology, and a unique electropharmacologic profile. The choice of treatment is dictated by the severity of symptoms, and ranges from observation for asymptomatic patients, to antiarrhythmic agents for those who are mildly to moderately symptomatic (eg, palpitations), to catheter-based ablation for those with more troubling symptoms or those who develop tachycardia-mediated cardiomyopathy. Antiarrhythmic therapy can be effective for arrhythmia suppression, and radiofrequency ablation has a high success rate (> 90%) with few procedural complications. In general, ventricular outflow tract tachycardia has a favorable prognosis. Exclusion of arrhythmogenic right ventricular dysplasia/cardiomyopathy is important due to significant disparities in prognosis and treatment.

Entities:  

Year:  2007        PMID: 17897564     DOI: 10.1007/s11936-007-0055-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  30 in total

Review 1.  Electrocardiographic recognition and ablation of outflow tract ventricular tachycardia.

Authors:  Rupa Bala; Francis E Marchlinski
Journal:  Heart Rhythm       Date:  2006-11-17       Impact factor: 6.343

2.  Sex-specific triggers for right ventricular outflow tract tachycardia.

Authors:  F E Marchlinski; M P Deely; E S Zado
Journal:  Am Heart J       Date:  2000-06       Impact factor: 4.749

3.  Idiopathic ventricular outflow tract tachycardia.

Authors:  A Farzaneh-Far; B B Lerman
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

4.  Magnetic resonance imaging abnormalities in right ventricular outflow tract tachycardia and the prediction of radiofrequency ablation outcome.

Authors:  Rungroj Krittayaphong; Pairash Saiviroonporn; Thananya Boonyasirinant; Supaporn Nakyen; Prajak Thanapiboonpol; Wipawin Watanaprakarnchai; Krongkarn Ruksakul; Charuwan Kangkagate
Journal:  Pacing Clin Electrophysiol       Date:  2006-08       Impact factor: 1.976

5.  Adenosine-sensitive ventricular tachycardia: right ventricular abnormalities delineated by magnetic resonance imaging.

Authors:  S M Markowitz; B L Litvak; E A Ramirez de Arellano; J A Markisz; K M Stein; B B Lerman
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

6.  Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract.

Authors:  Ravi K Yarlagadda; Sei Iwai; Kenneth M Stein; Steven M Markowitz; Bindi K Shah; Jim W Cheung; Vivian Tan; Bruce B Lerman; Suneet Mittal
Journal:  Circulation       Date:  2005-08-15       Impact factor: 29.690

7.  Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias.

Authors:  Robert J Kim; Sei Iwai; Steven M Markowitz; Bindi K Shah; Kenneth M Stein; Bruce B Lerman
Journal:  J Am Coll Cardiol       Date:  2007-05-04       Impact factor: 24.094

8.  Localization of optimal ablation site of idiopathic ventricular tachycardia from right and left ventricular outflow tract by body surface ECG.

Authors:  S Kamakura; W Shimizu; K Matsuo; A Taguchi; K Suyama; T Kurita; N Aihara; T Ohe; K Shimomura
Journal:  Circulation       Date:  1998-10-13       Impact factor: 29.690

9.  Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality.

Authors:  J S Gill; D Mehta; D E Ward; A J Camm
Journal:  Br Heart J       Date:  1992-10

10.  Mechanism of repetitive monomorphic ventricular tachycardia.

Authors:  B B Lerman; K Stein; E D Engelstein; D S Battleman; N Lippman; D Bei; D Catanzaro
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.